Blue Ridge Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Blue Ridge Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-563,800	Closed	-$51.2M	–	42
2017 Q2	$51.2M	Sell	563,800 -31,200	-5%	-$2.84M	0.9%	35
2017 Q1	$52.2M	Hold	595,000	–	–	0.68%	37
2016 Q4	$49.3M	Sell	595,000 -205,000	-26%	-$17.6M	0.62%	40
2016 Q3	$74M	Hold	800,000	–	–	0.88%	35
2016 Q2	$62.2M	Sell	800,000 -200,000	-20%	-$17M	0.8%	37
2016 Q1	$82.5M	Sell	1,000,000 -540,000	-35%	-$43.9M	1%	35
2015 Q4	$161M	Hold	1,540,000	–	–	1.8%	28
2015 Q3	$162M	Sell	1,540,000 -580,000	-27%	-$77.5M	1.87%	26
2015 Q2	$290M	Sell	2,120,000 -110,000	-5%	-$13.6M	3.27%	10
2015 Q1	$278M	Hold	2,230,000	–	–	3.17%	10
2014 Q4	$202M	Hold	2,230,000	–	–	2.45%	17
2014 Q3	$161M	Buy	2,230,000 +130,000	+6%	+$8.54M	1.9%	26
2014 Q2	$131K	Buy	2,100,000 +40,000	+2%	+$2.42M	1.29%	33
2014 Q1	$141M	Hold	2,060,000	–	–	1.55%	30
2013 Q4	$145M	Buy	2,060,000 +310,000	+18%	+$21.1M	1.49%	30
2013 Q3	$126M	Hold	1,750,000	–	–	1.51%	30
2013 Q2	$97.5M	Buy	+1,750,000	New	+$109M	1.18%	37

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blue Ridge Capital's BMRN Position: Q3 2017 in Review

Blue Ridge Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 563,800 shares — an estimated $51.2M sold.

Blue Ridge Capital first reported a position in BMRN in Q2 2013 and held it in 17 quarters. The position peaked at $290M in Q2 2015. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

Blue Ridge Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Blue Ridge Capital sold 563,800 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $51.2M.
Blue Ridge Capital first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Blue Ridge Capital's BioMarin Pharmaceuticals position peaked at $290M in Q2 2015.
411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Blue Ridge Capital's 13F filing for Q3 2017, filed 14 Nov 2017.